This guideline provides guidance on all aspects of CMV infection in haematopoietic stem cell transplant recipients. It covers donor and recipient CMV testing, primary and secondary CMV prophylaxis, CMV monitoring by polymerase chain reaction (PCR) and treatment of established CMV infection.
This guideline is written to assist in the management of patients undergoing haematopoietic stem cell transplantation (HSCT). The guidance covers risk factors for CMV infection, clincial manifestations of CMV infection, recipient and donor screening, primary prophylaxis, CMV monitoring, pre-emptive therapy and management of CMV disease.
The guidance may also be helpful in the management of patients who have not had an allogeneic HSCT but who have been treated with significant T cell suppressive therapy.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.